Clinical Trials - Patient

Clinical Trials - Patient

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Study of the Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (MT-3724NHL001)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study Testing the Addition of the Antibody Atezolizumab to Chemotherapy with Liposomal Doxorubicin and Bevacizumab in Recurrent Ovarian Cancer (GY009)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate Ribociclib in Combination with NonSteroidal Aromatase Inhibitor for the Treatment of Women with Advanced Breast Cancer Who have Received No Prior Therapy (19004) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of INCB053828 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer Harboring FGF/FGFR Alterations (15228) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the Combination of GSK2857916, Bortezomib, and Dexamethasone Compared with Daratumumab, Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (18230) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Trial Assessing The Tolerability Of Palbociclib In Combination With Letrozole Or Fulvestrant In Patients Aged 70 And Older With Estrogen Receptor Positive, Her2-Negative Metastatic Breast Cancer (A171601) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (GU17-295) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (A151216) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Observational Study Assessing the Clinical Effectiveness of the VeriStrat Test and Validating Immunotherapy tests in Subjects with NonSmall Cell Lung Cancer (BDX-00146)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label Study of ASP9801, an Oncolytic Virus Administered by Intratumoral Injection in Patients with advanced/metastatic Solid Tumors (9801-CL-0101 I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label Study of Intratumoral Tavo Plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment (PISCES) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody in Patients with Relapsed/Refractory Follicular Lymphoma (R19179-ONC-1625)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label Study to Assess the Safety and Tolerability and Pharmacokinetics of Capivasertib in Combination with Novel Agents in Patients with Castration Resistant Prostate Cancer (D3618C00002) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated NonSmall Cell Lung Cancer (GO40241)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab and in Combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of Head and Neck, NonSmall Cell Lung Cancer, Urothelial Cancer, and Other Cancers (CP-MGA271-03 I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
An Open-Label Study of Itacitinib in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis (17085) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (GU002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Blood Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Chemotherapy Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study (228-17)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Clinical Trial Evaluating Post- Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After (B51) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Comparison Study of Thoracic Radiation Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide (RTOG-0538) (C30610) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Crizotinib vs Placebo for Patients with Tumors Harboring the ALK Fusion Protein (E4512) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
De-Escalation Protocol of HPV Mediated Oropharyngeal Squamous Cell Carcinaoma Based on the American Joint Committee on Cancer Care 8th Edition Staging Manual (MECC-HN01)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members